Description de l'image

Preclinical proof of concept of AF243 potency to prevent and/or treat sensorineural hearing loss.


The objective of the AFHELO project is to complete and optimize the preclinical development of AF243, second lead drug candidate of Affichem and to extend its field of therapeutic action in the two main types of hearing loss related to age and noise.

To this end, Affichem has partnered with two European centers of scientific excellence: GIGA, Interdisciplinary Cluster for Applied Genoproteomics of the University of Liège in Belgium and the CSIC, the Spanish National Research Council.

 

Therefore, AFHELO includes direct studies of the potency of AF243 use for prevention and/or treatment of sensorineural Hearing Loss in humans, which is to date an unmet medical need and development of knowledge and know‐how that will be suitable for other studies. Altogether these statements fit with the European Innovation Partnership “Active and Healthy Ageing” objective of increasing the average number of healthy life years by two for European people in 2020.

Affichem S.A. -

Toulouse (France)


Description de l'image

Agencia Estatal Consejo Superior de Investigaciones Científicas -

Madrid (Spain)

This project is supported through Coordination

Theme 1 (Health) of the European Community's FP7.

Grant agreement number FP7-HEALTH-2012-INNOVATION-2-304900.

Description de l'image

Université de Liège,

Giga Neurosciences -

Liège (Belgium)

Description de l'image
Bookmark and Share

Copyright AFHELO 2012-2015